The JUPITER lipid lowering trial and vitamin D: Is there a connection?

Dermato-Endocrinology

Volumn 2, Issue 2, 2010, Pages 50-54

  Ware, William R ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cardiovascular disease; Heart disease; JUPITER; Rosuvastatin; Statins; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; C REACTIVE PROTEIN; COLECALCIFEROL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; VITAMIN D; VITAMIN D RECEPTOR;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; METABOLIC SYNDROME X; MORTALITY; OBESITY; PATHOGENESIS; PLEIOTROPY; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STROKE; SUDDEN DEATH; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 78751488474     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.2.2.13235     Document Type: Review

References (38)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008; 359:2195-207.
2. Eisenberg T, Wells M. Statins and Adverse Cardiovascular Events in Moderate-risk Females: A Statistical and Legal Analysis with Implication for FDA Preemption Claims. J Emperical Legal Studies 2008; 5:507-50.
3. Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a metaanalysis. Int J Cardiol 2010; 138:25-31.
4. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials. Circulation 2010; 121:1069-77.
5. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010; 152:488-96.
6. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-30.
7. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-82.
8. Giovannucci E. Vitamin D and cardiovascular disease. Curr Atheroscler Rep 2009; 11:456-61.
9. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168:351-8.
10. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95:787-96.
11. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 2005; 28:1228-30.
12. Lee DM, Rutter MK, O'Neill TW, Boonen S, Vanderschueren D, Bouillon R, et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Eur J Endocrinol 2009; 161:947-54.
13. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 2009; 23:295-9.
14. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, et al. STATIN-D Study: Comparison of the Inf luences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D. Cardiovasc Ther 2010.
15. Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99:903-5.
16. Aloia JF, Li-Ng M, Pollack S. Statins and vitamin D. Am J Cardiol 2007; 100:1329.
17. Sood A, Arora R. Vitamin D Deficiency and Its Correlations With Increased Cardiovascular Incidences. Am J Ther 2009.
18. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115:846-54.
19. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168:1174-80. (Pubitemid 351831400)
20. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117:503-11.
21. Navi BB, Segal AZ. The role of cholesterol and statins in stroke. Curr Cardiol Rep 2009; 11:4-11.
22. Pilz S, Dobnig H, Fischer JE, Wellnitz B, Seelhorst U, Boehm BO, et al. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39:2611-3.
23. Lee P, Greenfield JR. 25-Hydroxyvitamin D and risk of stroke: possible mediation by statin therapy? Stroke 2009; 40:35-8.
24. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168:1629-37.
25. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality and all-cause mortality in older US Adults. J Am Geriatr Soc 2009; 57:1595-603.
26. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168:1340-9. (Pubitemid 351930842)
27. Pilz S, Dobnig H, Nijpels G, Heine RJ, Stehouwer CD, Snijder MB, et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf ) 2009; 71:666-72.
28. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner- Pammer A, Dimai HP, et al. Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography. J Clin Endocrinol Metab 2008; 93:3927-35.
29. Semba RD, Houston DK, Bandinelli S, Sun K, Cherubini A, Cappola AR, et al. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur J Clin Nutr 2010; 64:203-9.
30. Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010; 65:225-36.
31. Autier P, Gandini S. Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials. Arch Intern Med 2007; 167:1730-7.
32. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.
33. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009; 85:198-203.
34. Chowdhury TA, Boucher BJ, Hitman GA. Vitamin D and type 2 diabetes: Is there a link? Prim Care Diabetes 2009; 3:115-6.
35. Grimes DS. Are statins analogues of vitamin D? Lancet 2006; 368:83-6.
36. Marshall TG. Are statins analogues of vitamin D? Lancet 2006; 368:1234.
37. Borradale D, Kimlin M. Vitamin D in health and disease: an insight into traditional functions and new roles for the 'sunshine vitamin'. Nutr Res Rev 2009; 22:118-36.
38. Heaney RP. Vitamin D: criteria for safety and efficacy. Nutr Rev 2008; 66:178-81.